How to buy Checkpoint Therapeutics stock | $2.6

Checkpoint Therapeutics, Inc is a biotechnology business based in the US. Checkpoint Therapeutics shares (CKPT) are listed on the NASDAQ and all prices are listed in US Dollars. Checkpoint Therapeutics employs 8 staff and has a trailing 12-month revenue of around USD$1.1 million.

How to buy shares in Checkpoint Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Checkpoint Therapeutics. Find the stock by name or ticker symbol: CKPT. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Checkpoint Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$2.6, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Checkpoint Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Checkpoint Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Checkpoint Therapeutics share price

Use our graph to track the performance of CKPT stocks over time.

Checkpoint Therapeutics shares at a glance

• Key figures

Information last updated 2020-12-26.

Latest market close	USD$2.6
52-week range	USD$1.05 - USD$4.5
50-day moving average	USD$2.5172
200-day moving average	USD$2.415
Wall St. target price	USD$15
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.01

Buy Checkpoint Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Checkpoint Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Checkpoint Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Checkpoint Therapeutics price performance over time

Historical closes compared with the close of $2.6 from 2020-12-18

1 week (2021-01-08)	-5.11%
1 month (2020-12-16)	-5.80%
3 months (2020-10-15)	0.39%
6 months (2020-07-15)	57.58%

1 year (2020-01-15)	52.94%
2 years (2019-01-15)	-34.19%
3 years (2018-01-12)	3.7
5 years (2016-01-12)	N/A

Checkpoint Therapeutics financials

Revenue TTM	USD$1.1 million
Gross profit TTM	USD$-17,617,000
Return on assets TTM	-48.07%
Return on equity TTM	-102.05%
Profit margin	0%
Book value	$0.534
Market capitalisation	USD$191.4 million

TTM: trailing 12 months

Shorting Checkpoint Therapeutics shares

There are currently 2.1 million Checkpoint Therapeutics shares held short by investors – that's known as Checkpoint Therapeutics's "short interest". This figure is 0.4% down from 2.1 million last month.

There are a few different ways that this level of interest in shorting Checkpoint Therapeutics shares can be evaluated.

Checkpoint Therapeutics's "short interest ratio" (SIR)

Checkpoint Therapeutics's "short interest ratio" (SIR) is the quantity of Checkpoint Therapeutics shares currently shorted divided by the average quantity of Checkpoint Therapeutics shares traded daily (recently around 470029.49002217). Checkpoint Therapeutics's SIR currently stands at 4.51. In other words for every 100,000 Checkpoint Therapeutics shares traded daily on the market, roughly 4510 shares are currently held short.

However Checkpoint Therapeutics's short interest can also be evaluated against the total number of Checkpoint Therapeutics shares, or, against the total number of tradable Checkpoint Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Checkpoint Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Checkpoint Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0405% of the tradable shares (for every 100,000 tradable Checkpoint Therapeutics shares, roughly 41 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Checkpoint Therapeutics.

Find out more about how you can short Checkpoint Therapeutics stock.

Checkpoint Therapeutics share dividends

We're not expecting Checkpoint Therapeutics to pay a dividend over the next 12 months.

Checkpoint Therapeutics share price volatility

Over the last 12 months, Checkpoint Therapeutics's shares have ranged in value from as little as $1.05 up to $4.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Checkpoint Therapeutics's is 1.7747. This would suggest that Checkpoint Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Checkpoint Therapeutics overview

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in Phase I clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and Cosibelimab, a programmed death ligand-1 (PD-L1), which is in Phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was founded in 2014 and is headquartered in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Frequently asked questions

• What percentage of Checkpoint Therapeutics is owned by insiders or institutions?

  Currently 12.624% of Checkpoint Therapeutics shares are held by insiders and 21.396% by institutions.

• How many people work for Checkpoint Therapeutics?

  Latest data suggests 8 work at Checkpoint Therapeutics.

• When does the fiscal year end for Checkpoint Therapeutics?

  Checkpoint Therapeutics's fiscal year ends in December.

• Where is Checkpoint Therapeutics based?

  Checkpoint Therapeutics's address is: 2 Gansevoort Street, New York, NY, United States, 10014

• What is Checkpoint Therapeutics's ISIN number?

  Checkpoint Therapeutics's international securities identification number is: US1628281073

• What is Checkpoint Therapeutics's CUSIP number?

  Checkpoint Therapeutics's Committee on Uniform Securities Identification Procedures number is: 162828107